Immuno-oncology

No Preference

Typhim Vi Anti-polyssacharide Antibody for Primary Response in Hematological Malignancy

Wednesday, June 14
6:15 PM - 7:45 PM

Introduction
Infectious complications in hematological malignancy (HM) patients are the major cause of morbi-mortality. Antibody (Ab) response to protein and polysaccharide immunizations at early stages may have an important value for predicting patients prone to infections.


Objectives
To asses specific antibody response to polysaccharide and protein vaccine and the potential role of Typhim Vi in HM.


Methods
Observational study of the specific Ab response to polysaccharide and protein vaccine in a group of patients with recurrent infections and HM. All patients were immunized with PPV (Pneumo23), Salmonella Typhi (Typhim Vi) and Tetanus Toxoid (Diftavax) of Sanofi Pasteur MSD. Blood was drawn after 4 weeks post vaccination. Specific Ab concentrations in response to PPV,Typhim Vi and Diftavax were measured by ELISA (Binding Site, UK), defining 3-fold increase as normal response.


Results
Twenty-eight patients were studied (mean age 63±13; 21 women).
All patients underwent clinical and immunological examination and were classified as either:  Advanced stages (CLL n = 5, HL n= 1, NHL n=13) and early stages (MGUS; n=9). Twenty-one (75%) and 15 (53%) patients had protective anti-PCP and anti-TT baseline levels, respectively (12 presented both); while only 2 (7%) had anti-Typhim baseline antibodies. Nine patients (32%) responded to Typhim, 5 on the MGUS group, with one patients responding to all three vaccines. High discrepancy was observed in the three responses, suggesting the role of primary and secondary responses.


Conclusion
Anti-Typhim responses may add value to the immunological assessment of HM patients, in whom primary responses might better predict susceptibility to recurrent bacterial infections.

Juliana Ochoa-Grullón

Hospital Clinico San Carlos

Presentation(s):

    Send Email for Juliana Ochoa-Grullón

    C Benavente

    Hospital Clínico San Carlos

    Presentation(s):

      Send Email for C Benavente

      R Martínez

      Hospital Clínico San Carlos

      Presentation(s):

        Send Email for R Martínez

        C Pérez

        Hospital Clínico San Carlos

        Presentation(s):

          Send Email for C Pérez

          A Peña

          Hospital Clínico San Carlos

          Presentation(s):

            Send Email for A Peña

            A Rodríguez de la Peña

            Hospital Clínico San Carlos

            Presentation(s):

              Send Email for A Rodríguez de la Peña

              K Llano Hernández

              Hospital Clínico San Carlos

              Presentation(s):

                Send Email for K Llano Hernández

                E Rodríguez-Frías

                Hospital Clínico San Carlos

                Presentation(s):

                  Send Email for E Rodríguez-Frías

                  Kissy Guevara

                  Hospital Clínico San Carlos

                  Presentation(s):

                    Send Email for Kissy Guevara

                    C Orte Cano

                    Hospital Clínico San Carlos

                    Presentation(s):

                      Send Email for C Orte Cano

                      Silvia Sanchez-Ramon

                      Hospital Clínico San Carlos de Madrid

                      Presentation(s):

                        Send Email for Silvia Sanchez-Ramon


                        Assets

                        Typhim Vi Anti-polyssacharide Antibody for Primary Response in Hematological Malignancy



                        Attendees who have favorited this

                        Send Email for Typhim Vi Anti-polyssacharide Antibody for Primary Response in Hematological Malignancy